Skip to navigation Skip to content

Clinical Trial: H.P. Acthar Gel®

Share

Details
Type of MS: RRMS
Treatment mode of action: To reduce disease activity
Number of Subjects: 66
Medication: H.P. Acthar Gel®
Location: Arizona|Colorado|Florida|Georgia|Illinois|Indiana|Kansas|Michigan|New Mexico|New York|North Carolina|Ohio|Tennessee|Texas|Utah|Virginia|Washington
Institutions: Multiple, U.S. Contact Information
Valerie Carvajal
(800) 556-3314
clinicaltrials@mallinckrodt.com

Funding:

Mallinckrodt Pharmaceuticals

Description

Investigators are recruiting 66 people with relapsing-remitting MS who have had a relapse and did not experience recovery from the relapse after high-dose intravenous or oral steroids. This study aims to determine the safety and effectiveness of H.P. Acthar Gel® (repository corticotropin injection, Mallinckrodt Pharmaceuticals), a gel injected under the skin that is designed to provide extended release of steroids to treat acute MS relapse. 

Share


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.